<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04321499</url>
  </required_header>
  <id_info>
    <org_study_id>SHOX2 and PTGER4</org_study_id>
    <nct_id>NCT04321499</nct_id>
  </id_info>
  <brief_title>SHOX2_PTGER4 DNA Methlyation in Lung Cancer</brief_title>
  <acronym>Epi1</acronym>
  <official_title>Establishing a Non-invasive Diagnostic Biomarker Test for Early Diagnosis of Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Essen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Essen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Data on SHOX2 and PTGER4 DNA Methylation suggest possible use as a biomarker for early lung
      cancer diagnosis.

      In this study a control group consisting of COPD patients with a CT-scan of the chest no
      older than 6 weeks and a control group of patients with a nodule and ruled out diagnosis of
      lung cancer will be included.

      SHOX2 and PTGER4 will be analyzed via PCR.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Data on SHOX2 and PTGER4 DNA Methylation suggest possible use as a biomarker for early lung
      cancer diagnosis.

      In this study a control group consisting of COPD patients with a CT-scan of the chest no
      older than 6 weeks and a control group of patients with a nodule and ruled out diagnosis of
      lung cancer will be included.

      A total of 150 patients will be enrolled in this study. SHOX2 and PTGER4 will be analyzed via
      PCR of blood plasma samples.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2016</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>DNA Methylation at early stages of lung cancer</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">70</enrollment>
  <condition>Lungcancer</condition>
  <arm_group>
    <arm_group_label>lung cancer</arm_group_label>
    <description>stage IA-IIIA lung cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>benign nodules</arm_group_label>
    <description>ruled out lung cancer via Operation or CT-scan follow-up</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>lung cancer</intervention_name>
    <description>PCR for SHOX2 and PTGER4</description>
    <arm_group_label>benign nodules</arm_group_label>
    <arm_group_label>lung cancer</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        lung cancer, benign nodule
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        suspicious finding for lung cancer on CT-scan

        Exclusion Criteria:

          -  history significant for former malignant diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kaid Darwiche, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>head of deparment of interventional pneumology, Ruhrlandklinik, UHEssen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ruhrlandklinik, Department of Interventional Pneumology</name>
      <address>
        <city>Essen</city>
        <state>NRW</state>
        <zip>45239</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Weiss G, Schlegel A, Kottwitz D, KÃ¶nig T, Tetzner R. Validation of the SHOX2/PTGER4 DNA Methylation Marker Panel for Plasma-Based Discrimination between Patients with Malignant and Nonmalignant Lung Disease. J Thorac Oncol. 2017 Jan;12(1):77-84. doi: 10.1016/j.jtho.2016.08.123. Epub 2016 Aug 18.</citation>
    <PMID>27544059</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 23, 2020</study_first_submitted>
  <study_first_submitted_qc>March 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 25, 2020</study_first_posted>
  <last_update_submitted>March 23, 2020</last_update_submitted>
  <last_update_submitted_qc>March 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Essen</investigator_affiliation>
    <investigator_full_name>Kaid Darwiche</investigator_full_name>
    <investigator_title>Priv.-Doz. Dr. med. Kaid Darwiche, head of department of interventional pneumology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

